MART-1:27-35 peptide vaccine(NCI)(MART-1:27-35 peptide vaccine(NCI))

概要

基本信息

药物类型

合成肽疫苗、治疗性疫苗

别名-

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

皮肤黑色素瘤转移性黑色素瘤

原研机构

National Cancer Institute

在研机构-

非在研机构

National Institutes of Health Clinical Center

权益机构-

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 MART-1:27-35 peptide vaccine(NCI) 相关的临床试验

NCT00091104

/ Completed临床1期IIT

A Study in Metastatic Melanoma Using a Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 TCR-Gene Engineered Lymphocytes and Subsequent Peptide Immunization

RATIONALE: Inserting a laboratory-treated gene into a person's white blood cells may make the body build an immune response to kill tumor cells. Giving cyclophosphamide and fludarabine before a white blood cell infusion may suppress the immune system and allow tumor cells to be killed. Vaccines may make the body build an immune response to kill tumor cells. Aldesleukin may stimulate a person's white blood cells to kill tumor cells. Combining white blood cell infusion with vaccine therapy and aldesleukin may cause a stronger immune response and kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of gene-modified white blood cells when given together with cyclophosphamide, fludarabine, vaccine therapy, and aldesleukin and to see how well it works in treating patients with metastatic melanoma.

开始日期2004-07-01

申办/合作机构

National Institutes of Health Clinical Center

[+1]

NCT00006243

/ CompletedN/AIIT

Melanoma Vaccines: Differentiation Antigen Peptides (MART-1:27-35, Tyrosinase and Gp-100) as Immune Targets

This randomized pilot clinical trial studies vaccine therapy and sargramostim in treating patients with stage IV malignant melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as sargramostim, increase the number of white blood cells and platelets found in bone marrow or peripheral blood. Giving vaccine therapy together with sargramostim may be an effective treatment for malignant melanoma

开始日期2000-10-01

申办/合作机构

National Cancer Institute

100 项与 MART-1:27-35 peptide vaccine(NCI) 相关的临床结果

登录后查看更多信息

100 项与 MART-1:27-35 peptide vaccine(NCI) 相关的转化医学

登录后查看更多信息

100 项与 MART-1:27-35 peptide vaccine(NCI) 相关的专利（医药）

登录后查看更多信息

100 项与 MART-1:27-35 peptide vaccine(NCI) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
皮肤黑色素瘤	临床1期	美国	National Institutes of Health Clinical Center	2004-07-01
转移性黑色素瘤	临床1期	美国	National Institutes of Health Clinical Center	2004-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AACR2011	N/A	黑色素瘤	12	Vaccination with MART-1 (27-35), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) peptides given in-oil-adjuvant with TLR-9 agonist PF-3512676 and GMCSF	(願積衊遞選廠構顧齋艱) = 艱觸獵獵蓋鏇廠窪遞窪積蓋廠獵衊觸鬱鏇願憲 (艱窪艱簾鑰憲壓廠憲積 ) 更多	-	2011-04-15